Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023

Acasti Pharma Inc. has announced its alignment with the U.S. Food and Drug Administration (FDA) on the protocol for its pivotal Phase 3 trial of GTX-104, a novel injectable nimodipine formulation for intravenous infusion (IV), in patients hospitalized with aneurysmal subarachnoid hemorrhage (aSAH). The company also confirmed its planned initiation of the STRIVE-ON trial in aSAH patients in calen..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 6.
  • textsms

Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress

Eloxx Pharmaceuticals, a leader in ribosomal RNA-targeted genetic therapies for rare diseases, has highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress. The RaDaR natural history study indicates that patients with autosomal recessive COL4A4 mutations have the severest form of the disease, with a more rapid progression to kidney f..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 22.
  • textsms